Head and Neck Cancer Clinical Trial
— ARCAGE-NWEOfficial title:
Alcohol Related Cancers and Genetic Susceptibility in Europe Follow-up - North-West England
Human papilloma virus (HPV) is a recognised cause of some head and neck cancers. Important
questions remain however, regarding the role of specific types of HPV, their effect on
prognosis and different subtypes of oral, pharyngeal and laryngeal cancer, interaction with
other risk factors (such as smoking and alcohol), and potential geographical differences in
the effect of HPV.
Via the Alcohol-Related Cancers and Genetic Susceptibility in Europe (ARCAGE) study, which
is an international collaboartive case-control study conducted in 15 centres in 11 European
countries, and pooling our results with the HPV-AHEAD consortium, we will conduct a
systematic analysis of HPV subtypes known or suspected to be involved in head and neck
cancer. This will involve investigation of HPV risk by tumour site (oral, oropharynx,
hypopharynx, larynx), tumour stage, country, sex and age, and whether risk is modified by
exposure to other known or suspected carcinogens including tobacco, alcohol and medical
history.
It is intended that this work will contribute to the development of evidence that may feed
into treatment protocols for these cancers as well as evaluations of the feasibility for
extending HPV vaccine programs.
Status | Completed |
Enrollment | 141 |
Est. completion date | April 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Consent to follow-up and use of tissue samples Exclusion Criteria: - No existing consent |
Observational Model: Case-Only
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Blackburn Hospital | Blackburn | |
United Kingdom | Blackpool Victoria Infirmary | Blackpool | |
United Kingdom | Manchester Royal Infirmary | Manchester | |
United Kingdom | North Manchester General Hospital | Manchester | |
United Kingdom | The Christie Hospital | Manchester | |
United Kingdom | Royal Preston Hospital | Preston |
Lead Sponsor | Collaborator |
---|---|
University of Aberdeen | International Agency for Research on Cancer |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HPV type | From surgical/biopsy samples taken in 2002/2003, to be typed in 2014 | No | |
Secondary | Vital status | 2014 | No | |
Secondary | Cancer Reccurrence | 2002-2014 | No | |
Secondary | Secondary cancers | 2002-2014 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |